CognivAiD contains Croci Stigma, Ginkgo Folium and Ginseng Radix et Rhizoma


Clinical trials are a major step to translate pharmacological potential into clinical safety and efficacy

  • =Moleac’s first product, developed to address unmet needs in post-stroke and post-traumatic brain injury recovery.
  • =Over 50 scientific publications detail its pre-clinical and clinical pharmacology, as well as its efficacy and safety profile.
  • =Today, NeuroAiD is available in over 30 countries worldwide and benefits approximately to 35,000 patients each year.

We continue to invest in research to further expand the knowledge on NeuroAiD for Traumatic Brain Injury (TBI), Spinal Cord Injury and Cognitive Decline.

CognivAiD contains Croci Stigma, Ginkgo Folium and Ginseng Radix et Rhizoma

MLC 1501

  • =A new herbal formulation, developed by Moleac for post-stroke recovery. 2Investigational New Drug applications (IND), one for stroke, one for traumatic brain injury, have been opened by US-Food and Drug Administration (US FDA), and we have successfully completed the clinical pharmacology program.
  • =A large randomized double-blind confirmatory trial is to be initiated in 2022 to demonstrate the efficacy and safety of MLC1501 in post-stroke recovery.

We are dedicated to

finding, developing, and commercializing new medicine for the unmet medical needs of patients suffering from central nervous system diseases and injuries.

Ongoing clinical trials

Clinicaltrials.gov link – NCT04766281

Protocol Title – Safety and Efficacy of MLC901 (NeuroAiD II) in Patients with Moderate TBI: A Randomized Double-Blind Placebo Controlled Trial

Indication – Moderate Traumatic Brain injury

Recruitment status – Recruiting

Phase – 4

Location – Philippines

Clinicaltrials.gov link – NCT04861688

Protocol Title – A Randomized Double-blind, Placebo-controlled, Multi-centre Trial to Investigate the Efficacy and Safety of NeuroAiD II™ (MLC901) to Improve Cognitive Functioning in Non-surgical Mild Traumatic Brain Injury Patients

Indication – Mild Traumatic Brain injury

Recruitment status – Recruiting

Phase 3

Location – Russia